Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for AC Immune (ACIU) over the last 11 years, with Q3 2025 value amounting to $214.5 million.

  • AC Immune's Liabilities and Shareholders Equity fell 2390.5% to $214.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $942.7 million, marking a year-over-year increase of 3.55%. This contributed to the annual value of $263.6 million for FY2024, which is 2789.77% up from last year.
  • Latest data reveals that AC Immune reported Liabilities and Shareholders Equity of $214.5 million as of Q3 2025, which was down 2390.5% from $229.8 million recorded in Q2 2025.
  • In the past 5 years, AC Immune's Liabilities and Shareholders Equity registered a high of $283.5 million during Q4 2021, and its lowest value of $221524.5 during Q3 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $212.8 million (2022), whereas its average is $188.1 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 9992.05% in 2021, then surged by 10104457.33% in 2022.
  • Over the past 5 years, AC Immune's Liabilities and Shareholders Equity (Quarter) stood at $283.5 million in 2021, then crashed by 31.93% to $193.0 million in 2022, then increased by 6.78% to $206.1 million in 2023, then increased by 27.9% to $263.6 million in 2024, then decreased by 18.62% to $214.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $214.5 million in Q3 2025, compared to $229.8 million in Q2 2025 and $234.8 million in Q1 2025.